AI-generated summary
The authors report a multicenter randomized trial in 188 children with progressive vitiligo comparing an oral Janus kinase inhibitor plus 308-nm excimer laser with topical tacrolimus plus laser over 48 weeks. The oral combination was associated with significantly higher repigmentation rates, with mild to moderate adverse events. The trial was single-blind, with a limited sample size and follow-up.
- Participants
- 188
- Who or what was studied
- Children aged 2 to 18 years with progressive vitiligo
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The single-blind design, limited sample size and follow-up, and single comparator restrict generalizability regarding long-term efficacy and safety.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Primary outcome, Sample size. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.